Merck's All-Cash Deal to Value Terns at $6 Billion, Financial Times Reports

Merck is reportedly set to acquire Terns in an all-cash transaction, valuing the company at approximately $6 billion, according to the Financial Times. This acquisition highlights Merck's strategic move to expand its portfolio and strengthen its position in the pharmaceutical industry. The deal is expected to enhance Merck's capabilities and market reach, providing significant growth opportunities. Further details about the transaction and its implications for both companies are anticipated as the deal progresses.